Introduction
The utilization of dialysis or continuous renal replacement therapy (CRRT) in critically ill post-cardiosurgical children with acute renal failure (ARF) ranges from 1% to 17 % of cases. [1] [2] [3] Continuous veno-venous hemodiafiltration (CVVH) is used as one of the modalities of CRRT in pediatric intensive care units. ARF is still a frequent complication following extensive pediatric cardiac surgery due to low cardiac output, massive hemolysis and high fluid overload. In our collection of 7 children with congenital heart disease requiring postoperative renal replacement, CVVH without extracorporeal membrane oxygenation (ECMO) achieved a sur prisingly low mortality.
The aim of our study was to investigate the use of CVVH in small children with ARF after cardiac surgery.
Methods
Retrospectively, we analyzed the clinical data of 7 children (< 15 y.o.) who required dialysis after cardiac surgery without ECMO from June 2005 to June 2008. The patient's files were reviewed for cardio-respiratory parameters and physiological variables at the start of CVVHDF and during dialysis. The data sheet included diagnosis, body weight, acid base status at the time beginning CVVH, duration of therapy and inotropic support, and outcome. CVVH with polymethylmethacrylate membrane (PMMA-CVVH) treatment was initiated in cases of low cardiac output, coagulation disorders and fluid overload. The definition of ARF was based on a 100% rise in serum creatinine concentration, oliguria (less than 1 ml/kg·h). On the other hand, CVVH was weaned in patients with satisfactory urine output (at least 2 ml/kg·h), stable biochemical markers of renal function and adequate fluid balance. Survival outcome was based on live discharge from hospital. Vascular access was provided by placing a 6-French (UK-cathe, Unitika Co. Ltd., Tokyo, Japan) or 8-French (Gam cathe, Gambro Co. Ltd., Tokyo, Japan) flexible double-lumen catheter in the internal jugular vein or the femoral vein. A PMMA membrane hemofilter (Hemofeel CH-0.3, Toray Medical Co. Ltd., Tokyo, Japan) was placed in the blood circuit to adsorb cytokines in the circulating blood (Fig. 1) . Nafamostat mesilate (Futhan, Torii Phamaceutical Co. Ltd., Tokyo, Japan) was used as the anticoagulant, with the dose adjusted to maintain an activated coagulation time of 150-180s. All data are expressed as a median with a full range. Statistical analysis was performed with non-parametric tests (Mann-Whitney U test and Wilcoxon matched-pair test). A P-value of less than 0.05 was considered significant.
Results
The 7 patients treated with PMMA-CVVH alone (4 boys, 3 girls) had a median age of 36 months (2 months to 7 years) and a median body weight of 11kg (3.9kg to 14.6 kg). Basic, clinical parameters are expressed in Table 1 . The cardiopulmonary bypass time ranged between 128 and 401 min (average time of 262 min) in 6 patients. The aorta clumping time ranged between 128 and 401 min (average time of 130 min) in 5 patients. The established time from cardiac operation to CVVH between 0 and 9 days (average time of 2.6 days). Operating conditions for PMMA-CVVH were as follows: blood flow rate 42.9 ± 15 (ml/min·m 2 ) (range: 21-68); dialysate flow rate, 11.3 ± 6.0 (ml/min·m 2 ) (range: 5.4-22.7). The lifetime of the single filter was 2.9 ± 2.0 days (range: 1.5-7.0). The overall duration of the procedure ranged from 2 to 38 days (average value of 13.3 ± 11.9 days). All patients were ventilated and used inotropic support at the commencement of CVVH. Laboratory and clinical data of CVVH efficacy are summarized in Table 2 . There was a significant decrease in the post-filter compared with pre-filter levels of BUN, creatine, potassium concentration in all patients. During the CVVH treatment, there were no significant changes in systolic blood pressure, lactate level and CRP; however, it was unnecessary for all patients to use epinephrine. They were all weaned from CVVH, and discharged from the hospital.
Discussion
The incidence of acute ARF requiring dialysis treatment after cardiac surgery with cardio-pulmonary-bypass (CPB) has been described to range between 1% and 17% depending on the complexity of procedure, entry criteria, and criteria for commencement of the dialysis treatment. The survival rate of 21%-70 % in infants with acute renal failure after cardiac surgery has been reported by several authors. [4] [5] [6] [7] CVVH is still an uncommon treatment in my PICU with an incidence of approximately 1%-2% per year. In this cohort of 7 children requiring vasoactive dosages, such as dopamine and epinephrine, PMMA-CVVH achieved a surprisingly high survival rate. The most recently published reports described low cardiac output, young age, low body weight, associated systemic disorders, high fluid overload on starting hemofiltration, pre-existing renal insufficiency or mechanical ventilation before surgery as additional risk factors. Especially, it has also been also suggested that higher fluid overload is related to cytokines. The mechanisms of cytokine removal by blood purification include convection, diffusion, and adsorption. The extent of cytokine removal by a particular blood purification therapy (utilizing any of these mechanisms alone or in combination with another) principally depends on the material and shape of the hemofilter/ hemodialyzer/ absorber used and the operating conditions employed. Cole et al. reported that CVVH reduced the dose of norepinephrine required to maintain circulation, a clinically useful effect. 8) Cornejo et al. also reported a decrease in the requirement of norepinephrine, an improved blood lactate level, and a high survival rate, all due to improvement of hemodynamics in their series. 9) Nakada found that PMMA-CVVH exhibited a higher capacity to remove cytokines than CHDF using a hemofilter made of a different material. 10) This high capacity for cytokine removal of PMMA-CVVH was principally ascribable to adsorption of cytokines to the hemofilter membrane.
Furthermore, blood cytokine levels in critically ill patients were significantly decreased after PMMA-CVVH treatment.
11) They also examined the clinical efficacy of PMMA-CVVH in patients with septic shock exhibiting extremely high blood IL-6 levels, and demonstrated a significant decrease in the blood IL-6 level during PMMA-CHDF treatment for 72 h. The high capacity of PMMA-CVVH to remove cytokines thus resulted in excellent therapeutic effects. His study also described that a significant decrease in blood lactate level during PMMA-CVVH. Ricci et al. reported that BNP levels were significant reduced after three and four days from PMMA-CVVH start.
12) The present study examined the CRP and Lactate level; however, there was no significant difference in all the parameter's levels after CVVH removal. They were all weaned from CVVH, and the many parameters such as BUN, creatine, potassium, CRP and Lactate level returned to the normal range on discharge from the Hospital. Although the mechanism by which improvement of hemodynamics occurs after PMMA-CVVH initiation remains to be determined in detail, it might entail removal of a cytokinemia 13) (estimated by measurement of blood CRP level), 
Conclusion
In conclusion, we analyzed the clinical date of 7 children requiring PMMA-CVVH after pediatric cardiac surgery, retrospectively. They were all weaned from CVVH, and the many parameters such as BUN, creatine, potassium, CRP and Lactate level returned to the normal range on discharge from the Hospital.
